Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etesevimab

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

- PMLiVE

Intercept gets EU nod for rare liver disease therapy

Ocaliva approved as a combination treatment for primary biliary cholangitis

- PMLiVE

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer

- PMLiVE

Novartis plans filing for lead CAR-T therapy early next year

Shows complete remission for 82 percent of paediatric and young adult B-cell ALL patients

- PMLiVE

Janssen files Stelara follow-up guselkumab in Europe

Trial data shows J&J’s drug is more effective in treating psoriasis than AbbVie’s Humira

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

Bristol-Myers Squibb (BMS) building

Opdivo gets green light for Hodgkin lymphoma in Europe

Becomes the first PD-1 inhibitor to receive EU licence in this indication

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links